Phase 2
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:

Drug Details

PLN-74809, is an oral once daily antifibrotic being studied for the treatment of idiopathic pulmonary fibrosis (IPF). PLN-74809 inhibits integrins αVβ1 and αVβ6, which in turn blocks activation of TGF-β, a central mediator of fibrosis. This upstream inhibition of TGF-β activation may prevent the formation of fibrotic tissue within the lung.

Study Purpose

A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

Find a Clinical Trial